Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.

Carmen F Nobre Matthew J NewmanAnne DeLisaPauline Newman

Published in: Cancer chemotherapy and pharmacology (2019)

Clinicians providing care for patients receiving moxetumomab pasudotox-tdfk should be aware of the strategies required for safe administration, including the management of serious adverse events.

Keyphrases

acute myeloid leukemia
palliative care
healthcare
acute lymphoblastic leukemia
single cell
cell therapy
multiple myeloma
diffuse large b cell lymphoma
bone marrow
hodgkin lymphoma
quality improvement